Open AccessStudy to Elucidate the Inhibitory Potential of Selected Flavonoids against Jab1 in Cervical Cancer
Publication year - 2021
Publication title -
biointerface research in applied chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 11
ISSN - 2069-5837
DOI - 10.33263/briac121.12901303
Subject(s) - hela , cancer , cervical cancer , mtt assay , inhibitory postsynaptic potential , cancer cell , in silico , cancer research , baicalein , pharmacology , medicine , biology , chemistry , cell growth , in vitro , biochemistry , gene
Jab1 has gained tremendous attention as a potent target in cancer therapeutics. Jab1 has been associated with the progression of numerous carcinomas by exhibiting several negative roles, such as degradation of tumor suppressor genes. We have mainly focused our research on elucidating inhibitory phytocompound (flavonoid) that could inhibit the Jab1 expression in cervical cancer, one of the most globally recognized gynecologic malignancies. Moreover, this study would provide a better targeted therapeutic approach for the management of cervical cancer. Although numerous flavonoids have presented potent cytotoxic and antitumor efficacy against HeLa cells, the inhibitory potential of some flavonoids against Jab1 has not been explored yet. Therefore, the current research aims to explore the inhibitory potential of flavonoids against Jab1 in cervical cancer. A total of eleven potent phytocompounds have been selected for screening potent phytocompound that could inhibit HeLa cancer cell growth via Jab1 downregulation. In silico findings demonstrated baicalein as the best Jab1 inhibitory phytocompound. Additionally, MTT assay and RT-PCR analysis have also strongly validated its inhibitory potential against Jab1 in cervical cancer. However, the further detailed analysis needed to be done to elucidate a novel mechanism that could help identify a novel and potent therapeutic phytocompound for drug development against cervical cancer.